Abstract
Members of the plasminogen-plasmin (PP) system participate in many physiologic functions. In particular, uPA, its receptor (uPAR) and its inhibitor PAI-1 play an important role in cell migration, cell proliferation and tissue remodeling. Through a number of interactions, these components of the PP system are also involved in the pathogenesis of many diseases. In cancer, they modulate the essential processes of tumor development, growth, invasion and metastasis as well as angiogenesis and fibrosis. Thus, quantification of uPA, uPAR and PAI-1 in tumors and, in some cases in the circulating blood, became of potential value in the prognostication of many types of cancer. These include cancer of the breast, stomach, colon and rectum, esophagus, pancreas, glioma, lung, kidney, prostate, uterine cervix, ovary, liver and bone. Published data are reviewed in this chapter. Clinical validation of the prognostic value has also been made, particularly in cancer of the breast. Inclusion of these biomarkers in the risk assessment of cancer patients is now considered in the risk-adapted management in carcinoma of the breast. Factors limiting its broader use are discussed with suggestions how these can be overcome. Hopefully the use of these biomarkers will be applied to other types of cancer in the near future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kwaan HC (1992) The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Dis 34(5):309–316
Castellino FJ, Ploplis VA (2005) Structure and function of the plasminogen/plasmin system. Thromb Haemost 93(4):647–654
Rijken DC, Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7(1):4–13
Declerck PJ, Gils A (2013) Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost 39(4):356–364, Mar 26, epub ahead of print
Vercauteren E, Gils A, Declerck PJ (2013) Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. Semin Thromb Hemost 39(4):365–372, Mar 26, epub ahead of print
Bouton MC, Boulaftali Y, Richard B, Arocas V, Michel JB, Jandrot-Perrus M (2012) Emerging role of serpinE2/protease nexin-1 in hemostasis and vascular biology. Blood 119(11):2452–2457
Ferraris GM, Sidenius N (2013) Urokinase plasminogen activator receptor: a functional integrator of extracellular proteolysis, cell adhesion, and signal transduction. Semin Thromb Hemost 39(4):347–355
Miles LA, Parmer RJ (2013) Plasminogen receptors: the first quarter century. Semin Thromb Hemost 39(4):329–337
Binder BR, Mihaly J, Prager GW (2007) uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist’s view. Thromb Haemost 97(3):336–342
Pepper MS (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 21(7):1104–1117
Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57(1):25–40
Kwaan HC (1992) The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11(3–4):291–311
Dano K, Behrendt N, Hoyer-Hansen G et al (2005) Plasminogen activation and cancer. Thromb Haemost 93(4):676–681
Kwaan HC, McMahon B (2009) The role of plasminogen-plasmin system in cancer. Cancer Treat Res 148:43–66
Deryugina EI, Quigley JP (2012) Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol 2012:564259
Carroll VA, Binder BR (1999) The role of the plasminogen activation system in cancer. Semin Thromb Hemost 25(2):183–197
Billroth T (1878) Lectures on surgical pathology and therapeutics. A handbook for students and practitioners. The New Sydenham Society, London
Carrel A, Burrows MT (1911) Cultivation in vitro of malignant tumors. J Exp Med 13(5):571–575
Tagnon HJ, Whitmore WF Jr, Schulman P, Kravitz SC (1953) The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer 6(1):63–67
Ossowski L, Quigley JP, Kellerman GM, Reich E (1973) Fibrinolysis associated with oncogenic transformation. Requirement of plasminogen for correlated changes in cellular morphology, colony formation in agar, and cell migration. J Exp Med 138(5):1056–1064
Astedt B, Holmberg L (1976) Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 261(5561):595–597
Kwaan HC, Mazar AP, McMahon BJ (2013) The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 39(4):382–391, Mar 26, epub ahead of print
Look MP, van Putten WL, Duffy MJ et al (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94(2):116–128
Janicke F, Prechtl A, Thomssen C et al (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93(12):913–920
Duffy MJ, Duggan C, Mulcahy HE, McDermott EW, O’Higgins NJ (1998) Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 44(6 Pt 1):1177–1183
Grondahl-Hansen J, Peters HA, van Putten WL et al (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1(10):1079–1087
Sternlicht MD, Dunning AM, Moore DH et al (2006) Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 15(11):2107–2114
Foekens JA, Buessecker F, Peters HA et al (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55(7):1423–1427
Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87(10):751–756
Harbeck N, Kates RE, Look MP et al (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62(16):4617–4622
Harbeck N, Kates RE, Schmitt M (2002) Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20(4):1000–1007
Harbeck N, Kates RE, Schmitt M et al (2004) Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5(5):348–352
Ji F, Chen YL, Jin EY, Wang WL, Yang ZL, Li YM (2005) Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer. World J Gastroenterol 11(21):3222–3226
Heiss MM, Babic R, Allgayer H et al (1995) Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13(8):2084–2093
Nekarda H, Schmitt M, Ulm K et al (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54(11):2900–2907
Zhang L, Zhao ZS, Ru GQ, Ma J (2006) Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol 12(25):3970–3976
Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS (1997) High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79(5):878–883
Stephens RW, Nielsen HJ, Christensen IJ et al (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91(10):869–874
Riisbro R, Christensen IJ, Nielsen HJ, Brunner N, Nilbert M, Fernebro E (2005) Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-receptor and biomarker group collaboration. Int J Biol Markers 20(2):93–102
Skelly MM, Troy A, Duffy MJ et al (1997) Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3(10):1837–1840
Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344(8919):401–402
Torzewski M, Sarbia M, Verreet P et al (1997) Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 3(12 Pt 1):2263–2268
Nekarda H, Schlegel P, Schmitt M et al (1998) Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 4(7):1755–1763
Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T (2000) Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 156(2):567–575
Hsu DW, Efird JT, Hedley-Whyte ET (1995) Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147(1):114–123
Landau BJ, Kwaan HC, Verrusio EN, Brem SS (1994) Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 54(4):1105–1108
Gutova M, Najbauer J, Gevorgyan A et al (2007) Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One 2(2), e243
Hataji O, Taguchi O, Gabazza EC et al (2004) Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 76(3):214–219
Pavey SJ, Hawson GA, Marsh NA (2001) Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 12(1):51–58
Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K (1996) Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78(3):487–492
Swiercz R, Wolfe JD, Zaher A, Jankun J (1998) Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 4(4):869–877
Shariat SF, Roehrborn CG, McConnell JD et al (2007) Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25(4):349–355
Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39(2):123–129
Hienert G, Kirchheimer JC, Pfluger H, Binder BR (1988) Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol 140(6):1466–1469
Kobayashi H, Fujishiro S, Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 54(24):6539–6548
Kuhn W, Schmalfeldt B, Reuning U et al (1999) Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79(11–12):1746–1751
De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S (1998) Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58(10):2234–2239
Hackel CG, Krueger S, Grote HJ et al (2000) Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 89(5):995–1003
Takeuchi Y, Nakao A, Harada A, Nonami T, Fukatsu T, Takagi H (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 88(11):1928–1933
Cantero D, Friess H, Deflorin J et al (1997) Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75(3):388–395
Lescaille G, Menashi S, Cavelier-Balloy B et al (2012) EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 12:115
Keer HN, Gaylis FD, Kozlowski JM, Bauer KD, Sinha AA, Wilson MJ, Kwaan HC (1991) Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate 18(3):201–214
Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM (1989) Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 142(1):193–198
Kirchheimer JC, Pfluger H, Ritschl P, Hienert G, Binder BR (1985) Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5(6):344–355
Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR (1999) Cancer invasion and tissue remodeling–cooperation of protease systems and cell types. APMIS 107(1):120–127
Kwaan HC, Keer HN, Radosevich JA, Cajot JF, Ernst R (1991) Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost 17(3):175–182
Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62(3):531–533
Ossowski L, Russo-Payne H, Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res 51(1):274–281
Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T (1994) Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemost 71(4):474–480
Yu HR, Schultz RM (1990) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50(23):7623–7633
Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H (1995) Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13(4):296–302
Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan HC (1995) Expresion of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in san athymic mouse model. J Clin Invest 96(6):2593–2600
Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K (1994) Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24(2):131–138
Bianchi E, Cohen RL, Thor AT, Todd RF 3rd, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54(4):861–866
de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144(1):70–81
Weidle UH, Wollisch E, Ronne E, Ploug M, Behrendt N, de Vries TJ, Quax PH, Verheijen JH, van Muijen GN, Ruiter DJ (1994) Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy. Ann Biol Clin 52(11):775–782
Pedersen H, Grondahl-Hansen J, Francis D et al (1994) Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54(1):120–123
Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG (1992) Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res 52(11):3043–3047
Kariko K, Kuo A, Boyd D, Okada SS, Cines DB, Barnathan ES (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53(13):3109–3117
Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312
Annecke K, Schmitt M, Euler U et al (2008) uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45:31–45
Schmitt M, Harbeck N, Brunner N et al (2011) Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 11(6):617–634
Thomssen C (2012) First planned efficacy analysis of the NNBC 3-Europe trial: addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. In: San Antonio breast cancer symposium, pp 1–1313
Jacobs VR, Kates RE, Kantelhardt E et al (2013) Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. Breast Cancer Res Treat 138(3):839–850
Nienaber V, Wang J, Davidson D, Henkin J (2000) Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite. J Biol Chem 275(10):7239–7248
Jensen JK, Thompson LC, Bucci JC et al (2011) Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem 286(34):29709–29717
Lin Z, Jiang L, Yuan C et al (2011) Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 286(9):7027–7032
Xu X, Gardsvoll H, Yuan C, Lin L, Ploug M, Huang M (2012) Crystal structure of the urokinase receptor in a ligand-free form. J Mol biol 416(5):629–641
Huai Q, Mazar AP, Kuo A et al (2006) Structure of human urokinase plasminogen activator in complex with its receptor. Science 311(5761):656–659
Law RH, Caradoc-Davies T, Cowieson N et al (2012) The X-ray crystal structure of full-length human plasminogen. Cell Rep 1(3):185–190
Meyer JE, Brocks C, Graefe H et al (2008) The oral serine protease inhibitor WX-671 – first experience in patients with advanced head and neck carcinoma. Breast Care (Basel) 3(s2):20–24
Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S (2013) Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer 108(4):766–770
Goldstein LJ, Oliveria CT, Heinrich B et al (2012) A randomized double-blindphase II study of the combination of WX-671 plus capecitabine vs. capecitabine monothrapry in first-line HER-2 negaive metastatic breast cancer (MBC). In: CTRC-AACR San Antonio breast cancer symposium, 5-20-01
Kriegbaum MC, Persson M, Haldager L et al (2011) Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets 12(12):1711–1728
Wang F, Eric Knabe W, Li L et al (2012) Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorg Med Chem 20(15):4760–4773
Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS (2011) Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 9(4):377–389
Gondi CS, Rao JS (2009) Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 487:267–281
Van Buren G 2nd, Gray MJ, Dallas NA et al (2009) Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 115(14):3360–3368
Rabbani SA, Ateeq B, Arakelian A et al (2010) An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 12(10):778–788
Bauer TW, Liu W, Fan F et al (2005) Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65(17):7775–7781
Kenny HA, Leonhardt P, Ladanyi A et al (2011) Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 17(3):459–471
Brooks TD, Wang SW, Brunner N, Charlton PA (2004) XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 15(1):37–44
Binder BR, Mihaly J (2008) The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett 118(2):116–124
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
McMahon, B.J., Kwaan, H.C. (2015). Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer. In: Scatena, R. (eds) Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology, vol 867. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7215-0_10
Download citation
DOI: https://doi.org/10.1007/978-94-017-7215-0_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7214-3
Online ISBN: 978-94-017-7215-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)